Comparative Pharmacology
Head-to-head clinical analysis: FOLICET versus FOLVITE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FOLICET versus FOLVITE.
FOLICET vs FOLVITE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Folic acid is reduced to tetrahydrofolate (THF) through the enzyme dihydrofolate reductase. THF is a cofactor in one-carbon transfer reactions involved in purine and pyrimidine synthesis, and amino acid metabolism, essential for DNA synthesis and cell division.
Folate is reduced to tetrahydrofolate (THF) which acts as a cofactor for single-carbon transfer reactions in nucleic acid and amino acid synthesis.
1 mg orally once daily. For treatment of megaloblastic anemia, up to 5 mg daily initially.
1 mg orally, intramuscularly, subcutaneously, or intravenously once daily for folic acid deficiency; for pregnant and lactating women: 0.4-0.8 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life is 3-5 hours in adults with normal renal function; may be prolonged up to 12-24 hours in severe renal impairment (CrCl <30 mL/min).
Terminal elimination half-life of folic acid is approximately 0.7 hours; for the active metabolite 5-methyltetrahydrofolate, half-life is 3–4 hours in plasma (tissue stores have a much longer turnover).
Primarily renal elimination: approximately 80% of the dose is excreted unchanged in urine via glomerular filtration and active tubular secretion. Biliary/fecal excretion accounts for <15%.
Primarily excreted unchanged in urine (hepatic metabolism minimal); after oral doses, fecal excretion occurs via unabsorbed drug and biliary secretion of folate metabolites accounts for a minor route.
Category C
Category C
Vitamin
Vitamin